Medication Treatment of Depression (January)

Date of Issue: 01/01/2003 | Volume: 1 | Number: 1

Issue Links: | Editorial Information

The first issue of The Carlat Psychiatry Report, covering depression treatments.

In This Issue

Article

St. John’s Wort: Wilting in America

America has not been kind to St. John’s Wort. In Europe, this flowering bush that blooms around June 24 (St. John’s Day), has been all the rage for about 2000 years. It was first mentioned by the Roman Pliny the Elder in the first century, and over the past two millennia it has been used for a variety of ills, including diarrhea, urinary problems, demonic exorcism, and more recently, for melancholia.

Read More
Article

Effexor XR: Is it really as good as they say it is?

Read More
Article

Lexapro: The Son of Celexa

Celexa (Citalopram) has been used in Europe since the late 1980s, and since its introduction in the U.S. market in 1998 it has made steady inroads into the SSRI market, largely because it has the reputation of being unusually well tolerated.

Read More
Article

Paxil CR: Paxil by any other name...

The latest member of the “controlled-release club” is GlaxoSmithKline, with its Paxil CR. While cynics may believe that CR launches are simply efforts to prolong patent-lives and therefore profits, the reality is that CR formulations are generally better tolerated and easier to dose.

Read More
Expert Q&A

Dr. John O’Reardon on Treatment-Resistant Depression

Dr. O’Reardon, I’d like to pick your mind about your approach to treatment resistant depression. First of all, how do you define it?

Read More
Anecdotes From The Field

Paxil CR

Dr. Richard Naimark, a psychiatrist in private practice at Chestnut Hill Counseling in Dover, New Hampshire, relates a tidbit that tempers TCR’s fairly lukewarm review of Paxil CR.

Read More
Tales From History

The First Antidepressant

Topics: Antidepressants

The first patient to receive a modern antidepressant was Paula J. F., a Swiss woman admitted to the Munsterlingen asylum with depression.

Read More